On September 15, LEADS BIOLABS-B rose 6.18% in regular trading, trading at 63.65 HKD/share, with turnover of approximately 29.81 million HKD.

On the news front, the company announced on September 14 that updated Phase II clinical data for its core product Welixin (opatuzumab, a PD-L1/4-1BB bispecific antibody) combined with chemotherapy for first-line treatment of non-small cell lung cancer (NSCLC) was presented as an oral report at the WCLC 2026 World Conference on Lung Cancer. In the non-squamous NSCLC PD-L1-positive subgroup, the objective response rate reached 81.8%, the disease control rate reached 100.0%, and the 6-month progression-free survival rate was 90.0%. The overall safety profile was favorable, comparable to PD-L1 monoclonal antibody combined with chemotherapy, with no new safety signals observed. The study enrolled 63 previously untreated NSCLC patients, with over 90% being Stage IV. The company is actively advancing Phase III clinical study planning for Welixin in first-line NSCLC. Notably, CLSA previously raised its target price for the company to 116.9 HKD.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)